CellCentric
PrivateLast Round
Series D
May 6, 2026
Est. Valuation
$900M
Total Funding Raised
$436.58M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
CellCentric is a biotechnology company that develops clinical-stage small-molecule inhibitors targeting p300/CBP for the treatment of multiple myeloma and other cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CellCentric Comparables
Compare CellCentric with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Karyopharm Therapeutics | 78% | |
| C4 Therapeutics | 74% | |
| Opna Bio | 74% |
For institutional investors. Book with your work email.
CellCentric Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 6, 2026 | ||||
| Series C | May 19, 2025 | ||||
| Series B | Jul 24, 2024 | ||||
| VC Round | Sep 11, 2023 | ||||
| Convertible Debt | Jul 11, 2023 | ||||
VC Round | Jan 26, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CellCentric Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series D, Series C |
| Forbion Capital Partners | Series C |
| RA Capital Management | Series D, Series C, Series B |
| Future Planet Capital Regional | Grant |
| Forbion | Series D, Series C |
| BrightEdge | Series C, Series B, VC Round |
| Morningside Ventures | VC Round, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2026
$220M round led by Venrock.
- Dec 19, 2025
Inobrodib enters Phase 3 trial for multiple myeloma and other cancers.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
On Sep 8th '26, CellCentric Limited appoints Paolo Pucci as a Non-Executive Director to strengthen its governance as it advances its clinical strategy.
- hiresSep 8, 2026
CellCentric Limited appoints Jason Cavalier as Chief Financial Officer on Sep 8th '26, strengthening its financial infrastructure, investor relations and capital markets capabilities as it advances its clinical strategy and prepares for its next phase of growth.
- hiresSep 8, 2026
CellCentric Limited appoints Jason Cavalier as Chief Financial Officer on Sep 8th '26, strengthening its executive leadership, financial infrastructure, investor relations and capital markets capabilities.
For institutional investors. Book with your work email.
CellCentric Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CellCentric's valuation, stock price, and market status.
Is CellCentric a public or private company?
CellCentric is a private company.
What is the current stock price of CellCentric?
CellCentric is a private company, so its shares have no public market price. Caplight tracks CellCentric's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CellCentric worth (valuation)?
CellCentric's valuation is estimated at $900.0M based on funding round data.
Can I buy CellCentric stock?
CellCentric shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CellCentric's last funding round?
CellCentric's most recent funding round was Series D on May 6, 2026.
Who are the main investors in CellCentric?
Key investors in CellCentric include Forbion Capital Partners, RA Capital Management, Forbion, Morningside Ventures, BrightEdge.
Will CellCentric IPO soon?
No public IPO plans have been announced for CellCentric.
How can I track CellCentric secondary market activity?
Caplight tracks bids, offers, and trades in CellCentric's shares on secondary markets.